GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
40.63
-0.20 (-0.49%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close40.83
Open40.71
Bid41.04 x 2200
Ask41.08 x 1200
Day's Range40.54 - 40.96
52 Week Range34.52 - 42.36
Volume2,443,643
Avg. Volume2,517,286
Market Cap99.241B
Beta (3Y Monthly)0.31
PE Ratio (TTM)40.96
EPS (TTM)0.99
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.96 (4.87%)
Ex-Dividend Date2018-11-15
1y Target Est44.30
Trade prices are not sourced from all markets
  • Gilead's Vemlidy Gets Approval in China for HBV Infection
    Zacks13 hours ago

    Gilead's Vemlidy Gets Approval in China for HBV Infection

    Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.

  • IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses
    Investor's Business Daily12 hours ago

    IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses

    Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo.

  • Glaxo Seeks Label Expansion of Nucala in Pediatric Patients
    Zacks13 hours ago

    Glaxo Seeks Label Expansion of Nucala in Pediatric Patients

    Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.

  • GlaxoSmithKline Stock Has Increased ~15% in 2018
    Market Realist14 hours ago

    GlaxoSmithKline Stock Has Increased ~15% in 2018

    On November 19, GlaxoSmithKline’s (GSK) stock price closed at $40.83, which represents ~1.21% growth from its close of $40.34 on November 16. GlaxoSmithKline’s stock price grew from $35.47 when the market closed on December 29, 2017, to $40.83 November 19, which reflects ~15% year-to-date growth.

  • Merck’s Stock Price Has Increased ~34% in 2018
    Market Realist16 hours ago

    Merck’s Stock Price Has Increased ~34% in 2018

    On November 16, Merck’s (MRK) stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15. Merck’s stock price grew from $56.79 when the market opened on January 2 to $76.06 when the market closed on November 16, which representing ~34% year-to-date growth. On November 16, Merck hit its 52-week high of $76.25.

  • Reuters21 hours ago

    Big pharma leaves big gaps: drugmakers urged to do more for poor

    Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday. The non-profit Access to Medicine Foundation (AMF) found companies overall were doing more than in the past to reach under-served populations, for example by setting lower prices for some drugs and improving transparency surrounding patents. What is more, research into urgently needed medicines for the developing world now relies on just a handful of companies, creating a fragile ecosystem where cutbacks by one player could have a significant impact on future supplies.

  • Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta
    Zacks2 days ago

    Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta

    Novartis (NVS) obtains FDA approval for the label expansion of Promacta. The CHMP also issues a positive opinion for the label expansion of Kisqali.

  • How Is Bausch Health’s Ortho Dermatologics Performing?
    Market Realist2 days ago

    How Is Bausch Health’s Ortho Dermatologics Performing?

    Bausch Health’s (BHC) wholly owned subsidiary Ortho Dermatologics generated revenues of $177.0 million in the third quarter. In the third quarter, Ortho Dermatologics’ net revenues remained flat compared to the third quarter of 2017. Ortho Dermatologics witnessed ~1% YoY organic revenue growth.

  • Key Updates on Facebook’s Workplace
    Market Realist2 days ago

    Key Updates on Facebook’s Workplace

    Workplace is not a secret Facebook (FB) project, but the company rarely discusses this business. During Facebook’s third-quarter conference call last month, for instance, executives talked a lot about Instagram, WhatsApp, Messenger, and Oculus. It was only after the conference call that word came out that Facebook is planning a major shift for Workplace.

  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of GSK.L earnings conference call or presentation 31-Oct-18 2:30pm GMT

    Q3 2018 GlaxoSmithKline PLC Earnings Call

  • AstraZeneca Shows It Can Still Take Some Knocks
    Bloomberg5 days ago

    AstraZeneca Shows It Can Still Take Some Knocks

    On Friday, the company said Imfinzi, its key lung cancer drug, had failed to deliver significant survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Rewind four years, and immuno-oncology – which enhances the body’s own ability to fight cancer – was a central pillar of Soriot’s defense. Concern about this pairing's performance in tests is one reason why it has taken until this year for AstraZeneca shares to climb above the 55 pounds-a-share proposal from Pfizer and stay there.

  • Merck's Keytruda Improves Survival in Esophageal Cancer Study
    Zacks6 days ago

    Merck's Keytruda Improves Survival in Esophageal Cancer Study

    Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.

  • Has GlaxoSmithKline plc (GSK) Outpaced Other Medical Stocks This Year?
    Zacks6 days ago

    Has GlaxoSmithKline plc (GSK) Outpaced Other Medical Stocks This Year?

    Is (GSK) Outperforming Other Medical Stocks This Year?

  • Bloomberg6 days ago

    Harvard Researcher's Startup Offers Genome Analysis for Free

    Nebula Genomics, devised by geneticist George Church to allow people to sell their DNA data for drug research and other uses, will provide complete DNA decoding at no charge for customers who answer a series of questions about their own health. The company begins offering its service Thursday and anyone is eligible to use it, Church said.

  • Financial Times6 days ago

    [$$] Business horrified by UK political turmoil over Brexit

    threatened to derail it, and the spectre of a “no deal” Brexit rose once more. Josh Hardie, deputy director-general of the CBI, said that, if the withdrawal agreement failing meant the UK crashing out of the EU without a deal, “it would be a disaster”.

  • GSK's Triangle nonprofit awards hit $4M after 10 years
    American City Business Journals7 days ago

    GSK's Triangle nonprofit awards hit $4M after 10 years

    After 10 years, GlaxoSmithKline and the Triangle Community Foundation have granted $4 million to local nonprofits as part of their annual Impact Awards.

  • Is GlaxoSmithKline (GSK) Right for Your Dividend Portfolio?
    Insider Monkey7 days ago

    Is GlaxoSmithKline (GSK) Right for Your Dividend Portfolio?

    “Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
    Zacks8 days ago

    Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe

    Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.

  • Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC
    Motley Fool8 days ago

    Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC

    Which stock wins in a matchup between these two big drugmakers?

  • Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
    Zacks9 days ago

    Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer

    Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.

  • Business Wire12 days ago

    Once-daily Trelegy Ellipta gains expanded COPD indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.

  • Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ
    Zacks13 days ago

    Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ

    Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.

  • Mylan: Why North America Is a Major Market
    Market Realist13 days ago

    Mylan: Why North America Is a Major Market

    In the third quarter, Mylan (MYL) reported net sales of $1.01 billion from the North American market, which is a 14% decline on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the revenue drop was due to reduced sales volumes of existing products, including Epipen. According to Mylan’s third-quarter earnings conference call, the lower sales volumes in the third quarter were due to the timing of customers’ purchases and the restructuring and remediation program that was started at the Morgantown manufacturing facility in the second quarter.

  • GlobeNewswire15 days ago

    Report: Developing Opportunities within Avon Products, Sanofi, Arch Coal, GlaxoSmithKline plc, Chimera Investment, and PTC — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE15 days ago

    Today's Research Reports on Trending Tickers: GlaxoSmithKline and Eli Lilly and Company

    NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...